Clinical trials, such as NCT03203369 and NCT04109482, are currently underway to evaluate the clinical efficacy and safety of anti-CD123 CAR T cells in BPDCN, with results still pending on ClinicalTrials.gov (Figure 3). Here, IL3RA is linked to CD4+/CD56+ hematodermic neoplasm.